The exact mechanism of action of anti-TNF antibodies in IBD is still uncertain, but there is a general consensus that one of their main therapeutic properties is mediated by binding to membrane-bound TNF (mTNF)-bearing immune cells in intestine mucosa. Here, TNF is linked to inflammatory bowel disease.